Jinlong J Jiang

US Patent:

7084156, Aug 1, 2006

Filed:

Nov 22, 2002

Appl. No.:

10/496615

Inventors:

Robert J. DeVita - Westfield NJ, US
Lehua Chang - Ramsey NJ, US
Danny Chaung - Clark NJ, US
MyLe Hoang - Colonia NJ, US
JinLong Jiang - Scotch Plains NJ, US
Peter Lin - Edison NJ, US
Andreas W. Sailer - Edison NJ, US
Jonathan R. Young - Kendall Park NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 215/38
C07D 215/16
A61K 31/47

US Classification:

514312, 514313, 514314, 546159, 546162, 546178

Abstract:

The present invention is concerned with compounds of the general Formula I:.

US Patent:

7217731, May 15, 2007

Filed:

Jan 26, 2005

Appl. No.:

11/043213

Inventors:

Jaime Lynn Bunda - Holland PA, US
Robert J. DeVita - Westfield NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Sander G. Mills - Scotch Plains NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/4035
C07D 209/44

US Classification:

514415, 548512

Abstract:

The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

US Patent:

7345083, Mar 18, 2008

Filed:

Mar 6, 2007

Appl. No.:

11/714352

Inventors:

Jaime Lynn Bunda - Holland PA, US
Robert J. DeVita - Westfield NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Sander G. Mills - Scotch Plains NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/4035
C07D 209/44

US Classification:

514415, 548512

Abstract:

The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

US Patent:

7645790, Jan 12, 2010

Filed:

Jan 26, 2005

Appl. No.:

10/586727

Inventors:

Jaime Lynn Bunda - Holland PA, US
Robert J. DeVita - Westfield NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Sander G. Mills - Scotch Plains NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4035
C07D 209/44

US Classification:

514415, 548512

Abstract:

The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

US Patent:

7652058, Jan 26, 2010

Filed:

Dec 12, 2005

Appl. No.:

11/792514

Inventors:

Robert J. DeVita - Westfield NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Sander G. Mills - Scotch Plains NJ, US
Jonathan R. Young - Southborough MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/407
C07D 491/052

US Classification:

514414, 548453

Abstract:

The present invention is directed to certain hydropyranopyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

US Patent:

7683068, Mar 23, 2010

Filed:

Jun 23, 2006

Appl. No.:

11/920286

Inventors:

Jinlong Jiang - Scotch Plains NJ, US
Robert J. DeVita - Westfield NJ, US
Sanjeev Kumar - Monroe NJ, US
Sander G. Mills - Scotch Plains NJ, US
Richard A. Tschirret-Guth - Lawrenceville NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/497
A61K 31/4035
A61K 31/4439
C07D 209/46
C07D 405/04
C07D 409/04
A61P 29/00

US Classification:

51425505, 514339, 514414, 514416, 544407, 5462771, 548465, 548472

Abstract:

The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

US Patent:

8124633, Feb 28, 2012

Filed:

Apr 7, 2008

Appl. No.:

12/593168

Inventors:

Robert J. DeVita - Westfield NJ, US
Sander G. Mills - Scotch Plains NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Andrew J. Kassick - Scotch Plains NJ, US
Jianming Bao - Princeton NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/422
C07D 209/02

US Classification:

514376, 514412, 548225, 548452

Abstract:

The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.

US Patent:

8394969, Mar 12, 2013

Filed:

Sep 21, 2009

Appl. No.:

12/563782

Inventors:

Brett C. Bookser - San Diego CA, US
Qun Dang - San Diego CA, US
Tony S. Gibson - San Diego CA, US
Hongjian Jiang - San Diego CA, US
De Michael Chung - Rowland Heights CA, US
Jianming Bao - Princeton NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Andy Kassick - Scotch Plains NJ, US
Ahmet Kekec - Hoboken NJ, US
Ping Lan - Dayton NJ, US
Huagang Lu - Plainsboro NJ, US
Gergely M. Makara - Budapest, HU
F. Anthony Romero - Westfield NJ, US
Iyassu Sebhat - Jersey City NJ, US
David Wilson - Brooklyn NY, US
Dariusz Wodka - Monmouth Junction NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4184
C07D 235/26
C07D 235/28
C07D 235/30

US Classification:

5483064, 514387, 514388

Abstract:

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.